Watson Pharmaceuticals downgraded to Neutral from Buy at Goldman Goldman downgraded Watson Pharmaceuticals due to valuation and the likelihood the company will have to make another large acquisition to sustain earnings growth. Price target lowered to $96 from $100.
News For WPI From The Last 14 Days
Check below for free stories on WPI the last two weeks.
